4-Demethyl-4-cholestryloxycarbonylpenclomedine — Competitive Intelligence Brief

4-Demethyl-4-cholestryloxycarbonylpenclomedine (4-Demethyl-4-cholestryloxycarbonylpenclomedine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topoisomerase II inhibitor. Area: Oncology.

phase 2 Topoisomerase II inhibitor Topoisomerase II Oncology Small molecule

Target snapshot

4-Demethyl-4-cholestryloxycarbonylpenclomedine (4-Demethyl-4-cholestryloxycarbonylpenclomedine) — DEKK-TEC, Inc.. 4-Demethyl-4-cholestryloxycarbonylpenclomedine is a chemotherapy medication that works by inhibiting the enzyme topoisomerase II.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
4-Demethyl-4-cholestryloxycarbonylpenclomedine TARGET	4-Demethyl-4-cholestryloxycarbonylpenclomedine	DEKK-TEC, Inc.	phase 2	Topoisomerase II inhibitor	Topoisomerase II
Idamycin Pfs	IDARUBICIN HYDROCHLORIDE		marketed	Anthracycline Topoisomerase Inhibitor	DNA, topoisomerase II	1990-01-01
Idamycin Pfs	Idarubicin Hydrochloride	Pfizer Inc.	marketed	Anthracycline topoisomerase inhibitor	DNA, Topoisomerase II	1990-01-01
Idamycin Pfs	Idarubicin Hydrochloride	Pfizer Inc.	marketed	Anthracycline topoisomerase inhibitor	DNA, Topoisomerase II	1990-01-01
Cipro	ciprofloxacin	Bayer AG	marketed	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Amekrin	AMSACRINE		marketed	amsacrine	DNA topoisomerase 2-beta, Solute carrier family 22 member 1, DNA topoisomerase II	1987-01-01
DOXORUBICIN HYDROCHLORIDE	DOXORUBICIN HYDROCHLORIDE		marketed		topoisomerase II	1974-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2029-04-21 — Cipro · 11369566 · Formulation · US
• 2029-04-21 — Cipro · 9603796 · Compound · US
• 2029-04-21 — Cipro · 9205048 · Method of Use · US
• 2029-12-11 — Cipro · 9233068 · Formulation · US
• 2030-04-27 — Cipro · 8318817 · Method of Use · US
• 2035-07-01 — Cipro · 9220796 · Formulation · US
• 2037-11-12 — Cipro · 11040004 · Method of Use · US
• 2038-11-27 — Cipro · 11246863 · Formulation · US

Sponsor landscape (Topoisomerase II inhibitor class)

1. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class
2. DEKK-TEC, Inc. · 1 drug in this class
3. Italian Sarcoma Group · 1 drug in this class
4. PETHEMA Foundation · 1 drug in this class
5. The University of Hong Kong · 1 drug in this class
6. Xanthus Pharmaceuticals, Inc. · 1 drug in this class